In this webinar, Zimmer & Peacock (ZP) explores the future of wearable biosensors, covering four key technologies: Sweat Sensors – Non-invasive but limited to analytes like lactate (glucose detection remains unproven). Microneedles – Minimally invasive, scalable, and ideal for multi-analyte monitoring (e.g., glucose + ketones). Transdermal Sensors – More invasive (e.g., Abbott’s Freestyle Libre), offering proven CGM performance but complex manufacturing. Implantable – Fully invasive, with ZP demonstrating live telemetry in fish and pigs. ZP highlights electrochemistry as the gold standard, powering scalable, low-sample biosensors. Their integrated sensor-to-cloud platform enables real-time analytics, demonstrated via a live caffeine detection demo. Key industry trends include: Decentralized diagnostics replacing lab-based testing. Emerging markets (e.g., India) adopting localized glucose monitoring. Microneedles gaining FDA traction (e.g., Biolink’s $270M funding). With ISO 13485-certified manufacturing, ZP offers expertise across all biosensor categories, supported by a robust patent portfolio. The session concludes with insights into regulatory challenges and the competitive CGM landscape. Watch now to learn how wearable biosensors are transforming healthcare.
